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Langerhans cells (LC) undergo a variety of phenotypic and 
functional changes in vitro. To determine the effects of gran-
ulocyte macrophage-colony-stimulating factor (GM-CSF), 
tumor necrosis factor-a (TNF-a), and interleukin 1-a (IL-l) 
on LC phenotype in vitro, epidermal cell suspensions were 
enriched for LC by density-gradient centrifugation and cul-
tured in the presence of 10 ng/ml of these cytokines. The 
percentage of cells expressing the surface protein COla was 
determined by flow cytometry. This percentage typically 
dropped after 48 h culture in both control and cytokine-
treated medium to less than half that of the starting value. By 
the fifth day, the percentage of cells expressing COla in 
TNF-a and IL-l-treated cultures was still near half of the 
starting value, slightly above that of control cultures. Treat-
ment with GM-CSF caused large and consistent decreases in 
the percentage of epidermal cells expressing COla. Cell via-
H uman Langerhans cells (LC) are bone marrow-derived dendritic cells [1 J that circulate to regional lymph nodes from the epidermis and are capable of inducing allogeneic, antigen specific, and cytotoxic T-cell proliferation [2-6]. LC express CD1a (T6) 
and class II major histocompatibility complex (MHC) antigens 
[5,7]. LC expression of class I MHC proteins is controversial; 
fres hly isolated epidermal LC express little or no class I MHC pro-
tein [8-10], whereas grafted LC in murine bone marrow chimeras 
have been shown to exrress significant levels of class I MH C protein 
in the host epidermis 11]. Human LC quickly lose CD1a expres-
Manuscript received January 22, 1990; accepted for publication May 11, 
1990. 
This work was done while Dr. Longley was supported as a Pfizer Scholar, 
and Dr. Kolenik was supported as an American Heart Association Fellow. 
Flow Cytometry was supported in part by the Yale Comprehensive 
Cancer Center Flow Cytometry/ Cell Sorting Core Facility, U.S. Public 
Health Service Grant CA-16359 from the National Cancer Institute. 
Reprint requests to: Dr. Jack Longley, Department of Dermatology, Yale 
University School of Medicine, New Haven, CT 06511. 
Abbreviations: 
GM-CSF: granulocyte macrophage-colony-stimulating factor 
JL-1 : interleukin 1-a 
LC: Langerhans cells 
MELR: mixed epidermal cell-lymphocyte reaction 
MHC: major histocompatibility complex 
PBS: phosphate-buffered saline 
TNF-a: tumor necrosis factor-a 
bility in each of the three cytokine-treated cultures was iden-
tical to the control cultures, with essentially all cells having 
died by the sixth day after isolation. To det~rmine the func-
tional effects of these cytokines, the cytokine-containing me-
dium was replaced after 72 h with medium containing puri-
fied allogeneic T cells and proliferation measured. 
Preliminary experiments showed no increased proliferation 
induced by IL-l or TNF-a-treated epidermal cells. GM-
CSF- treated epidermal cells induced 2- 3 times more T -cell 
proliferation than epidermal cells cultured without addi-
tional cytokines. We conclude that GM-CSF, a cytokine 
known to be produced by keratinocytes in vitro, decreases 
COla expression by human LC and increases their ability to 
stimulate proliferation by allogeneic T cells.] Invest Derma to! 
95:359-362, 1990 
sion and increase class I and class II MHC molecule expression when 
removed from the epidermis and placed in culture [10,12]. 
Freshly isolated LC are poor stimulators of allogeneic T cells in 
the mixed epidermal cell-lymphocyte reaction (MELR), but be-
come some of the most potent known stimulators of this reaction 
when maintained in culture for 2-3 d [6,10]. Studies in murine 
systems suggest that epidermally associated cytokines such as gran-
ulocyte macrophage-colony-stimulating factor (GM-CSF), tumor 
necrosis factor-a (TNF-a), and interleukin 1-a (IL-1) may influ-
ence the development of this ability in vitro [13 -15]. To determine 
how these cytokines affect the phenotype and function of human 
LC in vitro, we cultured purified LC from normal human skin with 
these cytokines and examined their expression of CD1a and their 
allogeneic stimulatory ability in the MELR. 
MATERIALS AND METHODS 
Isolation of Epidermal Cells Epidermal cells were separated as 
previously described (16]. Briefly, samples of normal skin were ob-
tained from plastic surgery specimens. The skin was trimmed to the 
dermis and incubated overnight at 4•c, dermal side down, in Tyr-
odes solution with 10 mg/ml Dispase (Boehringer Mannheim, In-
dianapolis, IN). The epidermis was peeled off and cell suspensions 
were obtained by incubation in 0.25% trypsin (Gibco, Grand Island, 
NY) at 3rC for 15 min, followed by mechanical disruption by 
vortexing and filtering through three layers of gauze (USP type VII, 
Johnson and Johnson, New Brunswick, NJ). Viable cells were 
enriched by density-gradient centrifugation over Histopaque 1077 
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(Sigma, St. Louis, MO) at 300 X g for 20 min at 4 oc. Cells remain-
ing at the interface were collected and viability assessed by trypan 
blue exclusion. This technique reliably yielded 97 - 100% living 
cells. As noted by Romani and colleagues (10], the percentage of 
CD1a+ ce lls was highly variable; in our hands a maximum of30% 
of cells expressed CD1a, but we routinely found greater than 95% 
of the CD1a+ cells at the interface. 
Immunofluorescence and Cytometry Cells were stained w ith 
the indirect technique as previously described [16). Briefly, the cells 
were incubated w ith a mouse monoclonal reacting with the CD1a 
protein (produced by the ATCC hybridoma CRL 8020) at a final 
concentration of 10 ,ug/ml in 1 ml phosphate-buffered saline (PBS) 
and 5% calf serum (GIBCO) for 1 h at 4 oc, pH 7.4. After washing 
twice w ith PBS and 5% calf serum, a second incubation was per-
formed with fluorescein isothiocyanate (FITC)-conjugated goat 
anti-mouse immunoglobulin (Becton-Dickinson, Mountain View, 
CA), 1,ug/1 06 cells, in 1 ml PBS with 5% calf serum for 1 h at 4 o C. 
After 2 more PBS washes (this time with 1% calf serum), the per-
centage of cells expressing CD1a was determined on a Becton-
Dickinson FACS-IV cell sorter. Controls included the omission of 
the primary antibody as well as irrelevant primary monoclonal anti-
body. 
Langerhans Cell Cultures After determination of CD1a posi-
tivity, cells were plated out at 106 CD1a+ cellsjml in 12-well flat-
bottom plates (Corning Glass Works, Corning, NY). The culture 
medium consisted ofRPMI1640 (GIBCO), 10% defined fetal bo-
vine serum (HyClone Labs Inc., Logan, UT), and 1% penicillin 
G/streptomycin/amphotericin B (GIBCO). Recombinant human 
GM-CSF, IL-1 (gifts of Dr. Steven Gillis, Immunex Corp., Seattle, 
WA), or TNF-a (courtesy of Dr. Thomas Kupper) were added to 
the experimental cultures to a final concentration of 10 ng/ml. This 
concentration of cytokines was chosen to give a maximum effect 
after .preliminary studies showed no difference between the effects 
of 50 or 10 ng/ml of each cytokine. 
Preparation ofT Cells Peripheral mononuclear cells were ob-
tained from the blood of healthy volunteers by centrifugation 
through Histopaque as above. Cells were suspended in culture me-
dium at a density of 107 cells/ml and monocytes allowed to adhere 
to a plastic culture flask (Corning Glass Works) for 3-12 h. Non-
adherent cells (lymphocytes) were then removed and incubated for 
1 h at room temperature with saturating amounts of an antibody 
that recognizes a framework determinant present on the class II 
MHC proteins HLA-Dr and HLA-Dp (produced by the IVA12 
hybridoma, ATCC #HB 145) . After washing, cells were then incu-
bated for 30 min at 37oC with an iron-conjugated goa t anti-mouse 
secondary antibody (Advanced Magnetics Inc., Cambridge, MA) 
and precipitated for 20 min to a magnetic plate (Advanced Mag-
netics Inc.). Nonmagnetic cells were then washed from the plate. 
This procedure was repea ted and reliably yielded a cel l suspension of 
94-97% T cell s, as assessed by expression of T -cel l receptor-
associated CD3 antigen by flow cytometry. 
Mixed Epidermal Cell-Lymphocyte Cultures Epidermal 
cel l suspensions enriched for LC were plated out in triplicate over a 
range of 0-3000 LC, 200 ,uijwell in 96-well round-bottomed 
plates (Corning Glass Works). Culture conditions and cytokine 
concentrations were as above. On day 3 of culture (72 h), the plates 
were centrifuged for 5 min at 300 X g and the medium replaced 
with th e RPMI (GIBCO). Plates were centrifuged again and RPMI 
replaced w ith medium containing 105 purified allogeneic T cell s 
but no added cytokines. These mixed epidermal cell - lymphocyte 
cultures were then incubated for 4 d more, pulsed with 1 ,uC of 
3H-thymidine (Amersham Inc., Arlington Heights, IL) per well, 
and harvested 16 h later, and the counts/min incorporated assessed 
with an LBK scintill ation counter. 
RESULTS 
Expression of CD1a The culture co nditions used were chose n 
to support T cell proliferation, not necessarily to grow LC. To 
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assure that the results. did not simply represent differential survival 
of LC in the different cultures, the percentage of viable ce!ls .'~as 
determined by trypan blue exclusion on days 0, 2, 3, and 5. Viability 
was virtual ly identical in control and cytokine-treated cultures, 
which showed steady cell death until day 6 of culture, by which 
time virtua lly all cells had died. In total, six experiments of r~e 
effects of cytokines on CDla expression were carried out usmg skin 
specimens from six separate individuals. The pattern of CDla e~­
pression by LC treated w ith cytokines versus control was mrular m 
all six cases. Figure 1 shows the mean of two such cases that are 
readi ly comparable due to their high and similar levels of CD la 
expression on day 0 (30% and 29.5%). Any given specimen yielded 
only enough LC for CD1a determinations on three days (day 0, day 
5, and one intermediate day), and we have therefore combmed rwo 
such experiments to better illustrate the time course of CDla ex-
pression over the 6-d period of LC viability in vi tro. By the second 
day of culture, the percentage of cells expressing CDla dropped 
from 30% on isolation to 12.4% in med ium alone (control group), 
13.5% with GM-CSF, 13.0% with IL-1 , and 11.0% with TNF-o:. 
By day 5 of culture, CD1a expression among control cel ls .dropped 
to 9.5%, whereas it was 13% in TNF-a-treated and 15%111 IL-l-
treated cells. Only 4.2% of GM-CSF-cultured cells were CDl a+ 
by day 5. The percentage of the cell s created with GM-CSF thar 
expressed CDla on day 5 of culture was less than half that ~f control 
cells or cell s created w ith IL-1 or TNF-a. Thus, the differences 
between the GM-CSF- treated cultures and the other cultures were 
large on day 5, and were statistically significant by a one-tailed 
Student t test, p = 0.01. As previously noted by Walsh andSe~mour 
(17], cultures treated with IL-1 showed a statistically s1gnificanr 
increase in the percentage of cells expressing CD1a compared to 
control cultures (p = 0.02 by a one-tailed Student t test). In our 
studies, however, the magnitude of the difference between IL-l-
treated and control cultures was not great. 
Allogeneic T-Cell Stimulation Preliminary experime~ts 
showed no increased stimulation by epidermal cells precultured lil 
IL-1 or TN F-a, and the remainder of the experiments were done 
only with GM-CSF- treated and control cultures. Eight ~uch e:--
periments were performed using surgical specimens from e1ght dif-
ferent patients. Epidermal cells precultured for 7~ h with GM~CSF 
were always more potent stimulators of allogeneic T-cell prohfera-
tion than cells cultured in medium alone. Figure 2 shows the results 
of triplicate cultures from a representative experiment using LC 
from one specimen and T cells from one donor. These data show 
increased allogeneic stimulation at all doses ofLC tested, as well as a 
direct ·rela tionship between the number of LC in culture and. the 
level ofT-cell proliferation, regardless of the culture condltlons 
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Figure 1. The percentage of epiderma l cells reta inin g CD la surface e..~­
pression in cultures treated with cytokines compared to control (untreated) 
cultures. Error bars, SEM. 
VOL. 95, NO. 3 SEPTEMBER 1990 
15000 
10000 
5000 
o GM-CSF 
• Control 
00~--~--L---~--~--~--~--~--~ 
1000 2000 3000 4000 
Langerhans Cell Number 
Figure 2. Allogeneic T-cell proliferation in response ro cytokine treated or 
control epidermal cells. Error bars, SEM of triplicate cultures. 
used. The differences between stimulation by GM-CSF-treated 
cells and control cells were significant at p < 0.01 at all doses ofLC 
tested, except at the lowest dose, where p = 0 .05 (one-tailed Stu-
dent t test). This general pattern was seen in all our co-cultivation 
experiments. These results indicate that GM-CSF is augmenting 
LC ability to stimulate allogeneic reactions on a cell-by-cell basis. 
There was no significant difference in the level ofT-cell prolifera-
tion observed in wells that contained GM-CSF or unaugmented 
medium but no LC, even though these wells were treated as if rhey 
did contain LC in the 72-h preculturing period . This observation 
precludes the possibility that the presence of contaminating GM-
CSF alone is responsible for the enhanced T-cell proliferation seen 
in G M -CSF- treated cui tures. 
DISCUSSION 
Most functional studies of human LC have involved crude epider-
mal cell suspensions. It is generally accepted that LC are the stimu-
lating cells because selective lysis of LC ablates the proliferative 
response and, therefore, it is reasonable to assume that this remains 
rrue in cyrokine-treated cultures (4,18]. Studies of murine and 
human epidermal cells have demonstrated that fresh ly isolated LC 
are poor stimulators of allogeneic T cells in the MELR (6,10]. 
W hen maintained in culture for 2-3 d, however, LC become po-
tent allogeneic T-cell stimulators [6 ,10]. These functional changes 
are associated with phenotypic changes, such as increased expres-
sion of class I and class II MHC molecules by both human and 
murine LC, and loss of expression ofCD1a by human LC [9, 10,12]. 
Experiments with murine LC have also shown that GM-CSF may 
accelerate and TNF-a may retard these phenotypic and functional 
changes [13-15]. 
CD1a is a cell-surface glycoprotein that has many similarities to 
class I MHC molecules, is expressed in a distribution that is recipro-
cal to these proteins in vivo (7,20,21], and has no clearly defined 
functional homologue in mice. As a result, it has been argued that 
CD1a represents a novel type of class I MHC molecule, and as such 
may be involved in the presentation of antigen toT cells [21]. Study 
of class I MHC expression by human LC is technically difficult 
because keratinocytes also express these molecules. However, as 
GM-CSF increases expression of class I MHC molecules by murine 
LC in vitro, we reasoned that it might have a reciprocal effect on 
CD 1a expression by human LC. Our studies support this hypothesis 
by showing that GM-CSF decreases CD1a expression by human 
LC. Although indirect, this finding also supports the hypothesis 
that GM-CSF has effects on human LC that are similar to its effects 
on murine LC. 
More direct support for the latter hypothesis comes from our 
demonstration that GM-CSF- treated human epidermal cell sus-
pensions have a markedly increased ability to stimulate proliferation 
of allogeneic T cells, similar to the effect of GM-CSF on murine 
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LC. Because keratinocytes can produce GM-CSF [19], it is possible 
that the exogenous GM-CSF used in these experiments merely sup-
plemented GM-CSF already present in the cultures, thus accelerat-
ing the phenotypic and functiona l changes. Although our experi-
ments with TNF-a- and IL-1- treated epidermal cells showed that 
they were slightly less efficient stimulating cells than the control 
cell s, the differences between these three groups were not large. As 
the effects of these cytokines on LC appear to be opposite to those of 
GM-CSF in murine systems, it is possible that endogenous GM-
CSF obscured an effect in our studies. 
It is not clear from our studies whether the observed effects of 
GM-CSF on LC are due to direct changes in LC physiology and 
phenotype or to the secondary production of other signalling mole-
cules. Studies using antibodies that block the effects of GM-CSF and 
other epidermal cytokines are being planned to address this ques-
tion. It is clear that the effects are not due to changes in LC viability, 
as viabi li ty was the same in all our experimental groups . In this way, 
our results differ from those in murine systems wl1ere GM-CSF and 
TNF-a appear to prolong LC viability in vitro (13,15]. However, 
because the culture conditions used were optimized forT-cell pro-
liferation rather than for epidermal cell growth, this finding should 
not be taken as evidence that these two cytokines are incapable of 
promoting human LC-growth. Our studies have shown that GM-
CSF produces some effects in cultured human LC that parallel those 
seen in murine LC and thus support the concept that GM-CSF may 
have an important role in the immune regulation of human skin. 
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